The DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) study18 will be important to establish whether improvements in outcomes in heart failure patients with LVEF ≥ 50% could be a class effect of sodium–glucose co-transporter 2 (SGLT2) inhibitors. The gene discussed is SLC5A2; the disease is heart failure.